Clostridium difficile is an important nosocomial pathogen, resulting in antibiotic-associated disease ranging from mild diarrhoea to the life-threatening pseudomembranous colitis. Upon antibiotic exposure, it is believed that the normal bowel microflora of patients is disrupted, allowing C. difficile to proliferate. Significantly, C. difficile is among only a few bacteria able to ferment tyrosine to p-cresol, a phenolic compound that is toxic to other microbes via its ability to interfere with metabolism. Therefore, the ability of different C. difficile strains to produce and tolerate p-cresol may play an important role in the development and severity of C. difficile-associated disease. In this study, it was demonstrated that two C. difficile hypervirulent 027 strains (Stoke Mandeville and BI-16) are more tolerant to p-cresol than other C. difficile strains including 630, CF4 and CD196. Surprising, it was shown that Clostridium sordellii also has a high tolerance to p-cresol, suggesting an overlap in the tolerance pathways in these clostridial species.
BartlettJ. G.1994; Clostridium difficile : history of its role as an enteric pathogen and the current state of knowledge about the organism. Clin Infect Dis 18 (Suppl. 4):S265–S272[CrossRef]
DepitreC.,
DelmeeM.,
AvesaniV.,
L'HaridonR.,
RoelsA.,
PopoffM.,
CorthierG.1993; Serogroup F strains of Clostridium difficile produce toxin B but not toxin A. J Med Microbiol 38:434–441[CrossRef]
ElsdenS. R.,
HiltonM. G.,
WallerJ. M.1976; The end products of the metabolism of aromatic amino acids by clostridia. Arch Microbiol 107:283–288[CrossRef]
LooV. G.,
PoirierL.,
MillerM. A.,
OughtonM.,
LibmanM. D.,
MichaudS.,
BourgaultA. M.,
NguyenT.,
FrenetteC.other authors2005; A predominantly clonal multi-institutional outbreak of Clostridium difficile -associated diarrhea with high morbidity and mortality. N Engl J Med 353:2442–2449[CrossRef]
LyerlyD. M.,
PhelpsC. J.,
TothJ.,
WilkinsT. D.1986; Characterization of toxins A and B of Clostridium difficile with monoclonal antibodies. Infect Immun 54:70–76
MyersG. S. A.,
RaskoD. A.,
CheungJ. K.,
RavelJ.,
SeshadriR.,
DeBoyR. T.,
RenQ.,
VargaJ.,
AwadM. M.other authors2006; Skewed genomic variability in strains of the toxigenic bacterial pathogen, Clostridium perfringens
. Genome Res 16:1031–1040[CrossRef]
PépinJ.,
SahebN.,
CoulombeM.-A.,
AlaryM.-E.,
CorriveauM.-P.,
AuthierS.,
LeblancM.,
RivardG.,
BettezM.other authors2005; Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile -associated diarrhea: a cohort study during an epidemic in Quebec. Clin Infect Dis 41:1254–1260[CrossRef]
PituchH.,
van BelkumA.,
van den BraakN.,
Obuch-WoszczatynskiP.,
Sawicka-GrzelakA.,
VerbrughH.,
Meisel-MikolajczykF.,
LuczakM.2003; Clindamycin-resistant, toxin A-negative, toxin B-positive Clostridium difficile strains cause antibiotic-associated diarrhea among children hospitalized in a hematology unit. Clin Microbiol Infect 9:903–904[CrossRef]
SebaihiaM.,
WrenB. W.,
MullanyP.,
FairweatherN. F.,
MintonN.,
StablerR.,
ThomsonN. R.,
RobertsA. P.,
Cerdeno-TarragaA. M.other authors2006; The multidrug-resistant human pathogen Clostridium difficile has a highly mobile, mosaic genome. Nat Genet 38:779–786[CrossRef]
SelmerT.,
AndreiP. I.2001; p -Hydroxyphenylacetate decarboxylase from Clostridium difficile . A novel glycyl radical enzyme catalysing the formation of p -cresol. Eur J Biochem 268:1363–1372[CrossRef]
SivsammyeG.,
SimsH. V.1990; Presumptive identification of Clostridium difficile by detection of p -cresol in prepared peptone yeast glucose broth supplemented with p -hydroxyphenylacetic acid. J Clin Microbiol 28:1851–1853
van den BergR. J.,
ClaasE. C. J.,
OyibD. H.,
KlaassenC. H. W.,
DijkshoornL.,
BrazierJ. S.,
KuijperE. J.2004; Characterization of toxin A-negative, toxin B-positive Clostridium difficile isolates from outbreaks in different countries by amplified fragment length polymorphism and PCR ribotyping. J Clin Microbiol 42:1035–1041[CrossRef]
WarnyM.,
PepinJ.,
FangA.,
KillgoreG.,
ThompsonA.,
BrazierJ.,
FrostE.,
McDonaldL. C.2005; Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet 366:1079–1084[CrossRef]